Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
BeOne terminates a MUC1-targeting project.
Welireg, Padcev, and a surprise fillip for Flare.
Two new pivotal Chinese first-line trials have started in lung cancer.
AZD0120’s first pivotal trial will test settings as early as the second line.
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
The company will start a phase 2/3 trial of PF-08634404 in March.
